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Abstract
Type 1 diabetes is one of the most common
endocrine problems in childhood and adolescence,
and remains a serious chronic disorder with increased
morbidity and mortality, and reduced quality of life.
Technological innovations positively affect the
management of type 1 diabetes. Closed-loop insulin
delivery (artificial pancreas) is a recent medical
innovation, aiming to reduce the risk of hypoglycemia
while achieving tight control of glucose. Characterized
by real-time glucose-responsive insulin administration,
closed-loop systems combine glucose-sensing and
insulin-delivery components. In the most viable and
researched configuration, a disposable sensor
measures interstitial glucose levels, which are fed into
a control algorithm controlling delivery of a rapid-
acting insulin analog into the subcutaneous tissue by
an insulin pump. Research progress builds on an
increasing use of insulin pumps and availability of
glucose monitors. We review the current status of
insulin delivery, focusing on clinical evaluations of
closed-loop systems. Future goals are outlined, and
benefits and limitations of closed-loop therapy
contrasted. The clinical utility of these systems is
constrained by inaccuracies in glucose sensing, inter-
and intra-patient variability, and delays due to
absorption of insulin from the subcutaneous tissue, all
of which are being gradually addressed.
Challenges for type 1 diabetes management
Type 1 diabetes is a chronic disease caused by T-cell-
mediated autoimmune destruction of the pancreatic b
cells in genetically predisposed individuals [1]. Insulin
discovery in the early 1920s transformed diabetes from a
uniformly fatal condition into a disease requiring life-
long insulin-replacement therapy. The Diabetes Control
and Complication Trial linked tight control of glucose
to prevention of long-term diabetes-related vascular
complications [2]. Intensification of insulin therapy has
become an essential treatment method, but it has been
hindered by an increased risk of hypoglycemia [3].
Severe hypoglycemia may lead to seizures or loss of con-
sciousness, and can be life-threatening. Fear of hypogly-
cemia by patients and caregivers may adversely affect
patients’ quality of life and psychological well-being [4],
and may result in ‘over-compensatory’ behaviors such as
overeating or taking less insulin [5].
Technological innovations continue to benefit the
management of type 1 diabetes. Novel rapid and long-
acting insulin analogs and more physiological insulin-
delivery systems including smart insulin pumps are
increasingly being used. Glucose monitoring is evolving,
leading to greater availability of subcutaneous continu-
ous monitors, which provide frequent, real-time, and
minimally invasive glucose measurements [6]. Sensor-
augmented pump therapy increases convenience by inte-
grating continuous glucose monitoring with an insulin
pump. Despite these advances, the current best manage-
ment of glucose control is still inadequate. Sensor-aug-
mented pump therapy is unable to prevent severe
hypoglycemia, with an incidence in patients using such
therapy similar to that observed in those using conven-
tional therapy [7]. Glucose levels in adults are above the
target glucose level of 10 mmol/l for more than 8 hours
per day, with even higher rates observed in the pediatric
and adolescent populations [8]. Automated systems
modulating insulin delivery according to sensor glucose
levels, independently of patient supervision, may be
needed to fully exploit existing glucose-sensing and
insulin-delivery technologies, and in particular to protect
against nocturnal hypoglycemia and minimize the
impact of noncompliant behaviors.
In this review, we examine the current status of
closed-loop insulin-delivery systems, extending previous
work [9-12], while focusing on their clinical applications
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and evaluations. Future goals are outlined, and the bene-
fits and limitations of closed-loop therapy contrasted.
Closed-loop insulin delivery
The artificial pancreas
Closed-loop insulin delivery, also referred to as the arti-
ficial pancreas, is an emerging therapeutic approach for
people with type 1 diabetes. It is a medical device con-
sisting of a linked continuous glucose monitor and an
insulin pump. Wireless communication facilitates auto-
mated data transfer between components without the
need for human intervention. A schematic view of the
artificial pancreas and the physiological feedback nor-
mally provided by the b-cell is shown in Figure 1.
The novelty of this approach resides in the real-time
feedback between glucose levels and insulin delivery,
similar to that presented by the b-cell. Insulin delivery is
modulated at intervals of 1 to 15 minutes, depending on
interstitial glucose levels, in contrast to the pre-pro-
grammed insulin delivery that takes place during con-
ventional insulin pump treatment.
The key component of the artificial pancreas is the
control algorithm, which directs insulin delivery accord-
ing to glucose levels while accounting for inherent mea-
surement errors and kinetic delays. Various algorithms
have been developed [13], but two main categories are
the most relevant: the proportional-integral-derivative
control (PID) [14,15] and the model-predictive control
(MPC) [16-18].
PID algorithms adjust insulin delivery by considering
deviations from a target glucose level (proportional
component), the area under the curve between the mea-
sured and the target glucose level (integral component),
and the rate of change in the measured glucose levels
(derivative component) [15].
MPC algorithms, by contrast, employ a mathematical
model of human glucose regulation to link insulin deliv-
ery and glucose excursions as described in numerous
theoretical, animal, and computer-simulation studies
[16,18-22]. Insulin delivery is calculated by minimizing
the difference between forecasted glucose concentrations
and the target glucose levels over a prediction window
of 1.5 to 3 hours, or longer.
MPC algorithms can be regarded as proactive; they
forecast glucose levels in anticipation of the glucose-
lowering effect of administered insulin and of
announced disturbances such as meals and physical
activity. PID algorithms, by contrast, can be considered
reactive, as they respond to observed glucose levels and
are less equipped to handle announced meals and
patient-directed insulin boluses. The safety of control
algorithms can be enhanced by a supervisory module,
which constrains insulin delivery by limiting the maxi-
mum insulin rate or by suspending insulin delivery
when glucose levels are low or decreasing rapidly
[23,24].
The MPC method is well suited to compensate for
time delays associated with the subcutaneous route of
insulin administration and interstitial glucose measure-
ments. Other algorithms have been tested clinically,
such as fuzzy logic, which is developed from qualitative
approximations of clinical judgment by diabetes
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Figure 1 An illustrative representation of a closed-loop insulin delivery system. (A) A sensor (black rectangle) transmits information about
interstitial glucose levels to a handheld device about the size of a cellphone (red box) which holds a control algorithm and interacts with the
user. An insulin pump (blue box in the pocket) delivers a rapid-acting insulin analog subcutaneously. Insulin delivery is modulated by the control
algorithm. The communication between the system components is wireless. The control algorithm can also reside within the insulin pump.
(Adapted from Hovorka [12]). (B) The closed loop replicates the physiological feedback normally provided by the b-cell.
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practitioners [25], a combination of MPC and PID algo-
rithms for insulin and glucagon delivery [19], or a PID
with insulin feedback [26]. One of the objectives of the
current research is to integrate existing control algo-
rithms within increasingly sophisticated insulin pumps
and continuous glucose monitors.
Progress thus far
It is anticipated that the artificial pancreas will evolve with
increasing technology sophistication and more compre-
hensive treatment objectives [27] (Table 1). Early genera-
tions of the artificial pancreas are likely to provide benefits
in terms of reduced incidence of hypoglycemia. Benefits
may be population-specific; for example, compliant, moti-
vated subjects may benefit from a reduced risk of hypogly-
cemia whereas less compliant subjects, including
adolescents, may benefit from reduced glucose levels. Fol-
low-up closed-loop applications may address hyperglyce-
mia, postprandial control and other lifestyle changes,
including exercise. Meals and exercise can be ‘announced’
to the control algorithm, and prandial insulin boluses can
be delivered in the conventional way simplifying closed-
loop operation. In a more challenging ‘fully closed-loop’
configuration, the control algorithm is not aware of meals
and exercise, and delivers insulin solely based on sensor
glucose levels. Glucagon coadministration can be used to
counteract peripheral overinsulization following insulin
boluses or delayed insulin absorption.
Apart from the low glucose suspend (LGS) approach
described below, which has entered postmarketing stage,
all other approaches are under investigation in con-
trolled laboratory conditions with realistic plans to per-
form studies under free-living conditions. Table 2
outlines the status and achievements of various closed-
loop approaches.
Approaches to reduce incidence of hypoglycemia
Low glucose suspend
Hypoglycemia associated with low sensor-measured glu-
cose levels sustained for 2 to 4 hours may lead to
seizures [28]. The body’s defensive mechanisms against
hypoglycemia are impaired during the night in people
with type 1 diabetes, who have lost the ability to release
the appropriate counter-regulatory hormones [29-32].
The simplest approach to reduce severity of hypoglyce-
mia is to interrupt insulin delivery. The LGS function
was the first example of a commercial application of
closed-loop insulin delivery. An insulin pump with an
integrated continuous glucose monitoring (CGM) (Para-
digm® Veo; Medtronic Diabetes, Northridge, CA, USA)
automatically suspends insulin delivery for up to 2
hours when hypoglycemia is detected and the hypogly-
cemia alarm is not acknowledged by the patient [33].
Patients may be unconscious during hypoglycemia, and
their ability to respond to alarms is reduced. Thus, a
considerable safety benefit may be obtained from the
LGS function. However, concerns have been raised
about the attendant hyperglycemia that can result, espe-
cially from false-positive hypoglycemia detection. The
hyperglycemia risk is not negligible, but thus far only
mild rebound hyperglycemia and minimal ketonaemia
have been reported after a temporary suspension of
insulin administration [34-38].
The LGS function aims to reduce the severity of hypo-
glycemia, but does not prevent it, which was the objec-
tive of work by Buckingham et al., who developed and
demonstrated, in laboratory settings, the effectiveness of
an algorithm to discontinue insulin delivery when pend-
ing hypoglycemia was predicted [39]. This approach was
investigated in adults in a clinical setting. Using a pump
shut-off time of 90 minutes and a glucose threshold of
4.4 mmol/l, 56% of hypoglycemic episodes were pre-
vented at a prediction horizon of 30 minutes, and 80%
when the horizon was extended to 45 minutes. This
approach was then tested overnight in young people, in
whom hypoglycemia was induced by gradually increas-
ing the subcutaneous insulin delivery [40]. Hypoglyce-
mia was prevented in up to 84% of cases, using five
prediction algorithms. All these prediction algorithms
used a 35-minute prediction horizon to allow time for
Table 1 Closed-loop approaches according to treatment objective
Objective Insulin-delivery modulation
Reduce severity and/or duration of
hypoglycemia
Suspension of insulin delivery at hypoglycemia (low glucose suspend)
Hypoglycemia prevention Pre-emptive suspension/reduction of insulin delivery before hypoglycemia occurs
Control to range Modulation (increase or decrease) of insulin delivery outside target range to limit hypoglycemia and
hyperglycemic excursions
Overnight glucose control Modulation of insulin delivery for nocturnal glucose control; lifestyle disturbances have limited effect
Closed-loop system with meal/exercise
announcement
Modulation of insulin delivery after meals using boluses administered by patient with announcement of
these, and exercise to the algorithm
Fully closed-loop system Modulation of insulin delivery when the control algorithm is unaware of meals, exercise, stress and other
lifestyle disturbances that affect glucose control; glucagon may be coadministered to reduce risk of
hypoglycemia
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the pump suspension to be effective in lowering insulin
levels once basal infusion was suspended.
Overnight closed-loop
Most severe hypoglycemic episodes occur during sleep
between midnight and 8 am [41]. As overnight glucose
control is not complicated by meals or physical activity,
closed-loop could help prevent nocturnal hypoglycemia.
This is a common clinical problem of great concern to
parents and carers of children with type 1 diabetes [42].
Over the past 4 years, diabetes research at Cambridge
University has focused on the development and testing
of overnight closed-loop insulin delivery systems. Clini-
cal studies have been performed in children, adults and
pregnant women [24,43,44], evaluating various scenarios
to reproduce real-life challenges for overnight glucose
control, which could potentially predispose to nocturnal
hypoglycemia, such as afternoon exercise or the con-
sumption of alcohol. Evening meals of different sizes
and compositions were also tested. An MPC algorithm
was used to determine basal insulin delivery according
to sensor glucose readings, whereas prandial insulin
boluses were administered based on the subjects’ stan-
dard practice. Most of those clinical studies adopted a
randomized crossover design comparing closed-loop
insulin delivery with the conventional insulin pump
therapy.
In these randomized crossover studies, the overnight
closed-loop system significantly increased the percentage
of time that plasma glucose levels were within a target
range of 3.9 to 8.0 mmol/l in children and adolescents
(from 40% to 60%, P = 0.002) and in adults (from 50%
to 76%, P < 0.001). The effectiveness of the closed-loop
system was most pronounced after midnight, when the
system became fully effective. Combined results of both
young and adult patients after midnight during closed-
loop and the conventional pump therapy are summar-
ized in Figure 2. Notably, these results indicate that the
closed-loop system resulted in a significantly reduced
time spent with glucose below the target range of 3.9
mmol/l both in young (from 4.1% to 2.1%, P = 0.03)
and adult (from 6.7% to 2.8%, P = 0.04) patients.
Fully closed-loop versus closed-loop with meal
announcement
Two main closed-loop approaches have been adopted in
the clinical studies for prandial insulin delivery: ‘fully
closed-loop’ and ‘closed-loop with meal announcement’
[9]. A fully closed-loop system delivers insulin without
information about the size or time of meals, whereas
information about meals together with information
about manually administered prandial insulin boluses is
provided to closed-loop systems adopting the ‘meal
announcement’ approach. In a hybrid system, the deliv-
ery of pre-meal insulin boluses remains one of the tasks
for which patients are responsible, with the closed-loop
system automatically determining the insulin delivery
between meals [27].
The hybrid system with meal-time priming boluses has
been shown to reduce postprandial hyperglycemia com-
pared to a fully closed-loop system [45]. As delays in insu-
lin absorption of the order of 30 to 100 minutes are a
major challenge for safe and effective postprandial glucose
control, this hybrid approach may be considered a transi-
tion step from ‘closed-loop with meal announcement’.
The feasibility and efficacy of MPC-based closed-loop
insulin delivery was also recently demonstrated in women
with type 1 diabetes throughout different stages of preg-
nancy [44]. Near-optimal nocturnal glycemic control was
obtained with the closed-loop system both in early and
late pregnancy, coping well with both the longitudinal
changes in insulin requirements and the insulin sensitivity
associated with pregnancy. Studies of a well-controlled
cohort of pregnant women suggested a reduced risk of
very low glucose levels with closed-loop insulin delivery,
but otherwise similar glucose control [46].
Glucagon coadministration has also been investigated
with the fully closed-loop approach [47,48]. Although
Table 2 Summary of achieved results
Objective/approach Status Results Ref.
Low glucose suspend Postmarketing studies Reduced nocturnal hypoglycemia in those with greatest risk; well- accepted
by patients
[61,62]
Suspend to prevent low
glucose
Laboratory studies;
home studies planned
Prevention of 80% of events of nocturnal hypoglycemia; effective as part of
overnight closed-loop system
[39,40]
Treat to range Laboratory testing
underway
- -
Overnight Laboratory studies;
home studies planned
Increased time spent in target glucose range by 20% in adolescents and
adults; reduced risk of nocturnal hypoglycemia
[24,43]
Meal announcement Laboratory studies Feasibility documented in children, adults, and pregnant women using
various control algorithms; preferred option by most investigators
[26,44,46,58,63]
Fully closed-loop Laboratory studies Feasibility documented in children and adults; addition of small prandial
bolus improves control; delayed insulin absorption/action remains a challenge
[25,45,64]
Fully closed-loop with
glucagon coadministration
Laboratory studies Feasibility documented in adults; glucagon helpful but cannot always
overcome insulin overdelivery
[47,48]
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effective in reducing the risk of hypoglycemia, glucagon
cannot be fully relied upon to reverse the effect of insu-
lin overdelivery.
Towards home studies
In silico testing
Evaluation of closed-loop systems in a controlled labora-
tory setting is an essential step to assess safety and effi-
cacy before moving to home settings, where everyday
life poses additional challenges for effective closed-loop
performance. In silico studies play a crucial role in com-
plementing clinical testing, and address scenarios that
cannot, for practical or ethical reasons, be tested in clin-
ical studies [49-51].
A computer-based simulation environment developed
at Cambridge University builds on a model of glucose
regulation, glucose sensing and insulin-pump delivery. It
includes a virtual population of subjects with type 1
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Figure 2 Distribution of plasma glucose levels after midnight in young people and adults during (top panel) closed-loop and (bottom
panel) conventional insulin-pump therapy (continuous subcutaneous insulin infusion (CSII)). Vertical dashed lines indicate the threshold of
significant hypoglycemia (3.0 mmol/l) and the target glucose range of 3.91 to 8.0 mmol/l. Values at the top denote the percentage of plasma
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diabetes with a range of insulin-sensitivity and glucore-
gulatory parameters, to represent both inter-subject and
intra-subject variability [49] Pre-clinical in silico testing
enables us to assess scenarios that are expected to occur
rarely but could be potentially harmful. For example,
simulations can evaluate the system’s response to sen-
sor-data dropouts, large calibration errors, communica-
tion failures, unannounced meals, or errors in
carbohydrate estimation and thus bolus dosing [51]. Dif-
ferent CGM devices or different algorithms can be
tested. Another simulator has been accepted by the US
Food and Drug Administration to replace animal testing,
and has been widely used for this purpose [50]. The
simulator developed by the Medtronic team [52] has
complemented animal testing, and has been instrumen-
tal in tuning the Medtronic PID algorithm [26,45].
Transitional and early home studies
Transition to the outpatient studies could be performed
gradually with an intermediate phase under supervision
of the research team in the subject’s home, or at a tran-
sitional clinical or hotel-like research facility. The transi-
tion phase needs to emphasize education to operate the
closed-loop system correctly and confidently. Compe-
tency-assessment tools may be used to ensure subjects’
knowledge and ability. User acceptance and user friend-
liness are important aspects that may affect study
results, quality of life, and ultimately technology adop-
tion. Subjects’ satisfaction may be assessed by the use of
questionnaires or qualitative interviews [53].
Home testing of overnight closed-loop is feasible with
present technologies. Pilot studies may evaluate efficacy,
safety and utility over a short period of time, whereas
longer studies are needed to demonstrate effectiveness
on glycemic control and rates of hypoglycemia. Specific
challenges of day-time glucose control, such as meal
intake and exercise, will need to be considered when
moving to a full-time (24 hours a day, 7 days a week)
closed-loop system.
Expectations for clinical practice
The main goal of closed-loop therapy is to achieve good
glycemic control while reducing the risk of hypoglyce-
mia in people with type 1 diabetes. Although reduction
in HbA1c levels is a common key outcome expected by
the regulatory authorities, it is important to consider
that for some patients, avoidance of severe recurrent
hypoglycemia may be the more important focus.
Improvement in glycemic variability could be an impor-
tant target for those subjects with acceptable HbA1c
and low incidence of severe hypoglycemia. Results thus
far indicate that these targets may be achieved with
closed-loop therapy.
Despite the perceived benefits of closed-loop therapy,
it is essential to set realistic goals to keep up with
reasonable clinical expectations. Furthermore, the
impact of this novel treatment tool on quality of life
will need to be assessed. Current closed-loop systems
are limited by suboptimal performance of the available
system components, which include CGM devices, insu-
lin formulations, and insulin-delivery systems. For
example, the accuracy of commercially available CGM
devices is impaired by errors arising from incorrect
calibration, rapid glucose changes, and glucose levels
within the hypoglycemic range. Sensor failures may
lead to termination of closed-loop operation. Similarly,
reduced accuracy of insulin delivery at low volumes by
current insulin pumps could negatively affect the per-
formance of closed-loop systems in patients with low
insulin requirements. The reliability of wireless com-
munication between the components also needs to be
addressed.
Patient engagement in the daily use of closed-loop
systems is also of importance. It is possible that the
introduction of the artificial pancreas as an integral part
of diabetes management will change current clinical
practice. Although patients could be released from the
constant attention to insulin adjustments they presently
experience, their active engagement will still be needed
during prolonged exercise, illness, puberty or pregnancy,
which are associated with significant changes in insulin
sensitivity and requirements. For this reason, specific
training and education in the use of closed-loop therapy
will be needed by both patients and healthcare profes-
sionals. The benefits and limitations of the system will
also need to be clarified.
The future: perfecting closed-loop therapy
For closed-loop insulin delivery to be used widely,
improvements may need to increase effectiveness, safety,
and convenience gradually (Table 3). Specific challenges
include postprandial glucose control. Improved under-
standing of postprandial glucose fluctuations will pro-
vide additional information to refine control algorithms.
Research using stable glucose isotopes to measure gut
absorption of meals of different sizes or compositions is
underway [54]. A dual-hormone closed-loop approach is
also under investigation using, for example, pramlintide,
an amylin analog that is normally released by b-cells
along with insulin after a meal. Amylin delays glucose
absorption, thus improving post-meal glucose control
[55]. Similarly, a more physiologic approach will be
needed to cope with exercise-related changes in insulin
sensitivity.
A major turning point in the development of closed-
loop systems will be the introduction of insulin formu-
lations with faster absorption. With rapid-acting insu-
lin analogs, the maximum blood-glucose-lowering
effect occurs after up to 90 to 120 min. This lag
Elleri et al. BMC Medicine 2011, 9:120
http://www.biomedcentral.com/1741-7015/9/120
Page 6 of 9
constitutes one of the greatest challenges for closed-
loop systems, and availability of faster insulin analogs
or devices accelerating insulin absorption will even-
tually translate into more effective and safer insulin
delivery. These pharmaceutical developments are
ongoing [56,57].
Engineering factors needing further attention include
accurate insulin delivery at low rates, more reliable
CGM devices, dependable wireless communication, and
improved control algorithms. Human factors should
consider usability, safety and training/education compo-
nents. The availability of smaller and more user-friendly
devices might be particularly important for children
[42]. Telemonitoring is also seen as an additional feature
to enhance safety, although its practicability and utility
are yet to be established. The clinical team can be
informed about system malfunctions, subject compli-
ance, and the level of glucose control, with the possibi-
lity of remote algorithm updates.
An alternative to subcutaneous insulin delivery is
intraperitoneal insulin infusion, which restores the por-
tal/peripheral insulin concentration gradient. Renard et
al. evaluated the feasibility and efficacy of a closed-
loop system with an implantable insulin pump coupled
to a subcutaneous glucose sensor [58]. Further pro-
gress could be made with an intraperitoneal port to
bypass the limitations of implantable insulin pumps
[59].
Conclusions
Closed-loop insulin delivery presents a tangible treat-
ment option and may serve as a bridge to a cure for
type 1 diabetes until stem-cell therapy or similar long-
term biologic interventions become available. Closed-
loop insulin delivery may revolutionize not only the way
diabetes is managed but also patients’ perceptions of liv-
ing with diabetes, by reducing the burden on patients
and carers, and their fears of complications related to
diabetes, including those associated with low and high
glucose levels. The next step is to confirm the encoura-
ging results collected under controlled laboratory set-
tings in real-life conditions at home.
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